In the context of acute coronary syndrome (ACS), where myocardial hypoxia and increased cardiac workload are critical concerns, the reduction in blood pressure and circulating volume provided by SGLT2 inhibitors helps maintain adequate coronary perfusion [96]. The gene discussed is SLC5A2; the disease is acute coronary syndrome.